Cargando…

Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases

OBJECTIVE: Dysfunction in fibroblast growth factor receptor (FGFR) signaling has been reported in diverse cancer types, including non-small cell lung cancer (NSCLC). The frequency of FGFR aberrations in Chinese NSCLC patients is therefore of great clinical significance. METHODS: A total of 10,966 NS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Zhen, Liu, Zichuan, Ou, Qiuxiang, Wu, Xue, Wang, Xiaonan, Shao, Yang, Liu, Hongyan, Yang, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Compuscript 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185861/ https://www.ncbi.nlm.nih.gov/pubmed/33710807 http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0120

Ejemplares similares

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors
por: Javle, Milind, et al.
Publicado: (2023)

FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non‐small cell lung cancer
por: Theelen, Willemijn SME, et al.
Publicado: (2016)

Biological and clinical implications of FGFR aberrations in paediatric and young adult cancers
por: Brown, Lauren M., et al.
Publicado: (2023)

FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells
por: Yuan, Hong, et al.
Publicado: (2017)

The combined action of the intracellular regions regulates FGFR2 kinase activity
por: Lin, Chi-Chuan, et al.
Publicado: (2023)

Aberrations in FGFR1, FGFR2, and RIP5 Expression in Human Congenital Anomalies of the Kidney and Urinary Tract (CAKUT)
por: Kelam, Nela, et al.
Publicado: (2022)

Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use
por: Patani, Harshnira, et al.
Publicado: (2016)

Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment
por: Cowell, John K., et al.
Publicado: (2021)

Growth charts in FGFR2- and FGFR3-related faciocraniosynostoses
por: Ea, Caroline, et al.
Publicado: (2022)

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023)

Intrinsic FGFR2 and Ectopic FGFR1 Signaling in the Prostate and Prostate Cancer
por: Wang, Cong, et al.
Publicado: (2019)

Novel mutation detection of fibroblast growth factor receptor 1 (FGFR1) gene, FGFR2IIIa, FGFR2IIIb, FGFR2IIIc, FGFR3, FGFR4 gene for craniosynostosis: A prospective study in Asian Indian patient
por: Barik, Mayadhar, et al.
Publicado: (2015)

FGFR1 regulates proliferation and metastasis by targeting CCND1 in FGFR1 amplified lung cancer
por: Yang, Ying, et al.
Publicado: (2020)

LGG-20. LANDSCAPE OF FGFR ALTERATIONS IN PEDIATRIC AND AYA GLIOMAS
por: Nobre, Liana, et al.
Publicado: (2023)

Comprehensive Landscape of Cyclin Pathway Gene Alterations and Co-occurrence with FGF/FGFR Aberrations Across Urinary Tract Tumors
por: Jardim, Denis L F, et al.
Publicado: (2022)

FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy
por: Quintanal-Villalonga, Álvaro, et al.
Publicado: (2020)

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
por: Weickhardt, Andrew J., et al.
Publicado: (2022)

The Evaluation of FGFR1, FGFR2 and FOXO1 in Orofacial Cleft Tissue
por: Goida, Jana, et al.
Publicado: (2022)

FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma
por: Tao, Zhanchao, et al.
Publicado: (2022)

Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice
por: Yu, Youxi, et al.
Publicado: (2021)

FGF/FGFR signaling pathway involved resistance in various cancer types
por: Zhou, Yangyang, et al.
Publicado: (2020)

The Aberrant Expression of the Mesenchymal Variant of FGFR2 in the Epithelial Context Inhibits Autophagy
por: Nanni, Monica, et al.
Publicado: (2019)

Landscape of FGF/FGFR Alterations in 12,372 Chinese Cancer Patients
por: Zuo, Wei, et al.
Publicado: (2020)

Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study
por: Meric-Bernstam, Funda, et al.
Publicado: (2022)

Differential Specificity of Endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in Complex with KLB
por: Yang, Chaofeng, et al.
Publicado: (2012)

FGFR aberrations increase the risk of brain metastases and predict poor prognosis in metastatic breast cancer patients
por: Xie, Ning, et al.
Publicado: (2020)

Effects of FGFR Tyrosine Kinase Inhibition in OLN-93 Oligodendrocytes
por: Rajendran, Ranjithkumar, et al.
Publicado: (2021)

Association of FGFR3 and FGFR4 gene polymorphisms with breast cancer in Chinese women of Heilongjiang province
por: Jiang, Yongdong, et al.
Publicado: (2015)

Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas
por: Granberg, Kirsi J, et al.
Publicado: (2017)

Expression and clinical significance of FGFR1 and FGFR2 in laryngeal squamous cell carcinoma
por: Hu, Mengdie, et al.
Publicado: (2022)

FGFR families: biological functions and therapeutic interventions in tumors
por: Liu, Qing, et al.
Publicado: (2023)

Fetal microtia and FGFR2 polymorphism
por: Zhao, Ruilian, et al.
Publicado: (2019)

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
por: Zingg, Daniel, et al.
Publicado: (2022)

Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR
por: Lu, Hengyu, et al.
Publicado: (2020)

Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
por: Ruan, Ruiwen, et al.
Publicado: (2023)

Reciprocal regulatory mechanism between miR-214-3p and FGFR1 in FGFR1-amplified lung cancer
por: Yang, Ying, et al.
Publicado: (2019)

FGF/FGFR-related lncRNAs based classification predicts prognosis and guides therapy in gastric cancer
por: Chen, Qiuxiang, et al.
Publicado: (2022)

Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression
por: Ware, Kathryn E., et al.
Publicado: (2010)

FGFR1 promotes the stem cell-like phenotype of FGFR1-amplified non-small cell lung cancer cells through the Hedgehog pathway
por: Ji, Wenxiang, et al.
Publicado: (2016)

Clathrin- and Dynamin-Independent Endocytosis of FGFR3 – Implications for Signalling
por: Haugsten, Ellen Margrethe, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_u0bo40a8g394dv4fnilbuqu4gf